参考文献（References）
[1]      Zhou G X, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence [J]. J Biol Chem, 1992, 267(36):25873-25880
[2]      Chao J, Tillman D M, Wang M Y, et al. Identification of a new tissue-kallikrein-binding protein[J]. Biochem J, 1986, 239(2):325-331
[3]      Xiong W, Tang C Q, Zhou G X, et al. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein[J]. J Lab Clin Med, 1992, 119(5):514-521
[4]      Miao R Q, Chen V, Chao L, et al. Structural elements of kallistatin required for inhibition of angiogenesis [J]. Am J Physiol Cell Physiol, 2003, 284(6):C1604-C1613
[5]      Stadnicki A, Mazurek U, Plewka D, et al. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease [J]. Int Immunopharmacol, 2003, 3(7):939-944
[6]      Wang M Y, Day J, Chao L, et al. Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization[J]. Adv Exp Med Biol, 1989, 247B:1-8
[7]      Chao J, Miao R Q, Chen V, et al. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling[J]. Biol Chem, 2001,382 (1):15-21
[8]      Chai K X, Ward D C, Chao J, et al. Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4)[J]. Genomics,1994, 23(2):370-378
[9]      Chai K X, Chen L M, Chao J, et al. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli[J] J Biol Chem,1993,268(32):24498-24505
[10]  Chen V C, Chao L, Pimenta D C, et al. Identification of a major heparin-binding site in kallistatin[J]. J Biol Chem, 2001, 276(2):1276-1284
[11]  黄晓平，王晓，董浩，等. 重组人kallistatin蛋白在毕赤酵母中的高校表达及生物活性分析[J]. 生物工程学报(Huang X, Wang X, Dong H, et al. High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity [J]. Sheng Wu Gong Cheng Xue Bao)(Article in Chinese), 2010, 26(2):249-255
[12]  Chen V C, Chao L, Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis[J]. Biochim Biophys Acta, 2000, 1479(1-2):237-246
[13]  Chen V C, Chao L, Chao J. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein[J]. J Biol Chem, 2000, 275(51):40371-40377
[14]  Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors [J]. Curr Pharm Des, 2003, 9(7):553-566
[15]  Iozzo R V, San Antonio J D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena [J]. J Clin Invest, 2001, 108(3):349-355
[16]  Capila I, Linhardt R J. Heparin-protein interactions [J]. Angew Chem Int Ed Engl, 2002, 41(3):391-412
[17]  Munoz E M, Linhardt R J. Heparin-binding domains in vascular biology [J]. Arterioscler Thromb Vasc Biol, 2004, 24(9):1549-1557
[18]  Yin H, Gao L, Shen B, et al. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation [J]. Hypertension, 2010, 56(2):260-267
[19]  Cantley L C. The phosphoinositide 3-kinase pathway [J] Science,2002, 296(5573):1655-1657
[20]  Kerbel R S. Tumor Angiogenesis[J]. N Engl J Med, 2008,358(19):2039-2049
[21]  Shen B, Gao L, Hsu Y T, et al. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-enos signaling[J].Am J Physiol Heart Circ Physiol,2010,299(5):H1419- H1427
[22]  Chao J, Yin H, Yao Y Y, et al. Novel role of kallistatin in protection against myocardial ischemia- reperfusion injury by preventing apoptosis and inflammation [J].Hum Gene Ther,2006,17(12):1201-1213
[23]  Gao L, Yin H, S Smith R Jr, et al. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction [J]. Lab Invest, 2008, 88(11):1157-1166
[24]  Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism [J]. Cell, 1986, 47(6):921-928
[25]  Garg A K, Aggarwal B B. Reactive oxygen intermediates in Tnf signaling [J]. Mol Immunol, 2002,39(9): 509-517
[26]  Zandi E, Chen Y, Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and Nf-KappaB-bound substrate [J]. Science, 1998, 281(5381):1360-1363
[27]  Wang C R, Chen S Y, Wu C L, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation[J]. Arthritis Rheum, 2005,52(4): 1319-1324
[28]  Hsieh J L, Shen P C, Shiau A L, et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection[J]. Hum Gene Ther, 2009, 20(2):147-158
[29]  Shen B, Hagiwara M, Yao Y Y, et al. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress [J]. Hypertension, 2008, 51(5):1358-1365
[30]  Shiau A L, Teo M L, Chen S Y, et al. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin[J]. BMC Cancer, 2010, 10:245
[31]  Avruch J.Map kinase pathways:the first twenty years[J].Biochim Biophys Acta,2007,1773(8):1150- 1160
[32]  Shen B, Chao L, Chao J. Pivotal role of Jnk-dependent Foxo1 activation in downregulation of Kallistatin expression by oxidative stress[J].Am J Physiol Heart Circ Physiol,2010,298(3):H1048- H1054
[33]  Shen B, Smith RS Jr, Hsu Y T, et al. Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression [J]. J Biol Chem, 2009, 284(51):35471-35478
[34]  Diao Y, Ma J, Xiao W D, et al. Inhibition of angiogenesis and Hct-116 xenograft tumor growth in mice by kallistatin[J]. World J Gastroenterol, 2007, 13(34):4615-4619
[35]  Miao R Q, Agata J, Chao L, et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth[J]. Blood, 2002, 100(9):3245-3252
[36]  Diao Y, Zhao X F, Lin J S, et al. Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid[J]. World J Gastroenterol,2011,17(1):111-117
[37]  Tse L Y, Sun X, Jiang H, et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas [J]. J Gene Med, 2008, 10(5):508-517
[38]  Jiang X, Li H, Qiao H, et al. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice[J]. Cancer Sci, 2009, 100(11):2226-2233